Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Quality of life and measures of psoriasis severity
Brian Kirby
Psoriasis is a chronic lifelong skin condition that causes significant psychosocial morbidity but is rarely life-threatening. This simple sentence summarises the challenges inherent in treating the disease and assessing its severity. The understanding that psoriasis is a skin disease with psychological sequelae, and that these sequelae are not necessarily related to the amount of physical skin disease, led to objectively measuring the impact of psoriasis on quality of life. Inherent in any measure of quality of life is the psychological burden that patients with a disease have to endure.
Dermatology in practice
2006;
13
(5): 10–12
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
LEO Pharma receives MHRA approval for Anzupgo cream in chronic hand eczema
Galderma shares positive phase 3 data for nemolizumab in prurigo nodularis
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis trial
UCB’s Bimzelx approved by FDA to treat hidradenitis suppurativa
LEO Pharma announces long-term results for Adbry in atopic dermatitis
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy